Ansgar Deibel

Dr. Ansgar Deibel

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
CCChristophe Corpechot
Christophe Corpechot
FCFabrice Carrat
Fabrice Carrat
FGFarid Gaouar
Farid Gaouar
FCFrederic Chau
Frederic Chau
GHGideon Hirschfield
Gideon Hirschfield
VLVictor de Lédinghen
Victor de Lédinghen

27 October 2022 in JHEP Reports
Verified
Journal Article
Open access
BSbernhard scheiner
bernhard scheiner
DRDaniel Roessler
Daniel Roessler
SPSamuel Phen
Samuel Phen
MLMir Lim
Mir Lim
KPKatharina Pomej
Katharina Pomej
MPMatthias Pinter
Matthias Pinter
We investigated the efficacy and safety of immune checkpoint inhibitor (ICI) rechallenge in patients with hepatocellular carcinoma (HCC) who received ICI-based therapies in a previous systemic line. In this international, retrospective multicenter study, patients with HCC who received at least two lines of ICI-based therapies (ICI-1, ICI-2) at 14 institutions were eligible. The main outcomes included best overall response and treatment-related adverse events. Of 994 ICI-treated patients screened, a total of 58 patients (male, n = 41; 71%) with a mean age of 65.0±9.0 years were included. Median systemic treatment lines of ICI-1 and ICI-2 were 1 (range, 1-4) and 3 (range, 2-9), respectively. ICI-based therapies used at ICI-1 and ICI-2 included ICI alone (ICI-1, n = 26, 45%; ICI-2, n = 4, 7%), dual ICI regimens (n = 1, 2%; n = 12, 21%), or ICI combined with targeted therapies/anti-VEGF (n = 31, 53%; n = 42, 72%). Most patients discontinued ICI-1 due to progression (n = 52, 90%). Objective response rate was 22% at ICI-1 and 26% at ICI-2. Responses at ICI-2 were also seen in patients who had progressive disease as best overall response at ICI-1 (n = 11/21; 52%). Median time-to-progression at ICI-1 and ICI-2 was 5.4 (95% CI 3.0-7.7) months and 5.2 (95% CI 3.3-7.0) months, respectively. Treatment-related adverse events of grade 3-4 at ICI-1 and ICI-2 were observed in 9 (16%) and 10 (17%) patients, respectively. ICI rechallenge was safe and resulted in a treatment benefit in a meaningful proportion of patients with HCC. These data provide a rationale for investigating ICI-based regimens in patients who progressed on first-line immunotherapy in prospective trials. Therapeutic sequencing after first-line immune checkpoint inhibitor (ICI)-based therapy for advanced hepatocellular carcinoma (HCC) remains a challenge as no available second-line treatment options have been studied in immunotherapy-pretreated patients. Particularly, the role of ICI rechallenge in patients with HCC is unclear, as data from prospective trials are lacking. We investigated the efficacy and safety of ICI-based regimens in patients with HCC pretreated with immunotherapy in a retrospective, international, multicenter study. Our data provide the rationale for prospective trials investigating the role of ICI-based regimens in patients who have progressed on first-line immunotherapy.

27 April 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
PKPhilipp Andreas Kronenberg
Philipp Andreas Kronenberg
ADAnsgar Deibel
Ansgar Deibel
BGBruno Gottstein
Bruno Gottstein
FGFelix Grimm
Felix Grimm
BMBeat Müllhaupt
Beat Müllhaupt
PDPeter Deplazes
Peter Deplazes
Both alveolar (AE) and cystic echinococcosis (CE) are lacking pathognomonic clinical signs; consequently imaging technologies and serology remain the main pillars for diagnosis. The present study included 100 confirmed treatment-naïve AE and 64 CE patients that were diagnosed in Switzerland or Kyrgyzstan. Overall, 10 native Echinococcus spp. antigens, 3 recombinant antigens, and 4 commercial assays were comparatively evaluated. All native E. multilocularis antigens were produced in duplicates with a European and a Kyrgyz isolate and showed identical test values for the diagnosis of AE and CE. Native antigens and three commercial tests showed high diagnostic sensitivities (Se: 86–96%) and specificities (Sp: 96–99%) for the diagnosis of AE and CE in Swiss patients. In Kyrgyz patients, values of sensitivities and specificities were 10–20% lower as compared to the Swiss patients’ findings. For the sero-diagnosis of AE in Kyrgyzstan, a test-combination of an E. multilocularis protoscolex antigen and the recombinant antigen Em95 appears to be the most suitable test strategy (Se: 98%, Sp: 87%). For the diagnosis of CE in both countries, test performances were hampered by major cross-reactions with AE patients and other parasitic diseases as well as by limited diagnostic sensitivities (93% in Switzerland and 76% in Kyrgyzstan, respectively).

1 August 2021 in Gastrointestinal Endoscopy
Verified
Journal Article
Open access
ADAnsgar Deibel
Ansgar Deibel
LDLu Deng
Lu Deng
CCChih-Yuan Cheng
Chih-Yuan Cheng
MSMichael Schlander
Michael Schlander
TRTao Ran
Tao Ran
BMBenjamin Misselwitz
Benjamin Misselwitz
Screening for colorectal cancer (CRC) can effectively reduce CRC incidence and mortality. Besides colonoscopy, detection of biomarkers in stool, blood or serum, including fecal immunochemical test (FIT), ColoGuard, pro Epicolon and PolypDx have recently been advanced. We aimed to identify characteristics of theoretical, highly efficient screening tests and calculated effectiveness and cost-effectiveness of available screening tests. Using the microsimulation-based colon modeling open-source tool (CMOST), we simulated 142,501 theoretical screening tests with variable assumptions for adenoma and carcinoma sensitivity, specificity, test frequency and adherence, and identified highly efficient tests outperforming colonoscopy. For available screening tests, we simulated 10 replicates of a virtual population of 2 million individuals, using epidemiological characteristics and costs assumptions of the United States. Highly efficient theoretical screening tests were characterized by high sensitivity for advanced adenoma and carcinoma and high patient adherence. All simulated available screening tests were effective at 100% adherence to screening and at expected real-world adherence rates. All tests were cost-effective below the threshold of 100,000 U.S. dollars per life year gained. With perfect adherence, FIT was the most effective and cost efficient intervention whereas Epi proColon was most effective at expected real-world adherence rates. In our sensitivity analysis, assumptions for patient adherence impacted strongest on effectiveness of screening. Our microsimulation study identified characteristics of highly efficient theoretical screening tests and confirmed effectiveness and cost-effectiveness of colonoscopy and available urine-, blood- and stool-based tests. Better patient adherence results in superior effectiveness for CRC prevention in the whole population.

3 October 2025 in Journal of Hepatology
Verified
Journal Article
Open access
YWYu Jun Wong
Yu Jun Wong
LLLaurent Lam
Laurent Lam
PSPierre-Antoine Soret
Pierre-Antoine Soret
SLSara Lemoinne
Sara Lemoinne
BHBettina Hansen
Bettina Hansen
GGGlobal & ERN Rare-Liver PBC Study Groups
Global & ERN Rare-Liver PBC Study Groups
Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis (PBC). However, the frequency and clinical relevance of discordant biochemical and LSM changes remain unclear. We aim to determine the performance of the most recent or current LSM (LSMc) in predicting first hepatic decompensation (HD) in the setting of discordant biochemical and LSM responses. In this international, multicenter study, we included patients with at least two reliable LSM performed at least 6 months apart. Patients with prior HD, liver transplantation or hepatocellular carcinoma were excluded. Biochemical response was based on the Paris-II criteria. LSM response was defined as stable or any reduction in LSM. The primary outcome was the occurrence of the first HD. Secondary outcomes were liver transplantation and liver-related death. The influence of LSM on HD was estimated using Cox regression analysis. A total of 1,793 patients with PBC were analyzed. Over a median follow-up of 22 (IQR 12-39) months, 3.3% developed HD. Up to 55% of patients with PBC exhibited discordance between LSM and biochemical response. Among patients with LSM response, achieving Paris-II criteria was associated with a lower risk of HD (hazard ratio [HR] 0.25, 95% CI 0.06-0.97, p 10 kPa strongly predicted HD (HR 14.5, 95% CI 6.9-30.6, p <0.001), irrespective of biochemical response and prior LSM trajectories. Discordance between LSM and biochemical response is frequent. Most recent or current LSM is the strongest predictor of first liver-related events in patients with PBC, irrespective of prior biochemical response or LSM trajectory. Both liver stiffness measurement (LSM) and biochemical response have prognostic significance in patients with primary biliary cholangitis. However, the clinical relevance and how discordant biochemical and LSM changes should be best interpreted remain unclear. In this large international multicenter study, we demonstrated that once the current LSM is known, prior LSM trajectories and biochemical changes did not improve the prediction of liver-related events in patients with primary biliary cholangitis. Our finding addresses a common clinical dilemma in risk-stratifying PBC patients with discordant biochemical and LSM responses. Importantly, the use of the latest LSM value for risk prediction significantly simplifies the use of LSM in clinical decision-making for PBC patients with multiple LSM readings.

28 January 2022 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ADAnsgar Deibel
Ansgar Deibel
DSDaniel Stocker
Daniel Stocker
CSCordula Meyer zu Schwabedissen
Cordula Meyer zu Schwabedissen
LHLars Husmann
Lars Husmann
PKPhilipp Andreas Kronenberg
Philipp Andreas Kronenberg
BMBeat Müllhaupt
Beat Müllhaupt
Objectives: Alveolar echinococcosis (AE) is an orphan zoonosis of increasing concern in endemic areas, including Europe. It frequently presents in an advanced, inoperable stage, that requires life-long parasitostatic benzimidazole therapy. In some patients, long-term therapy leads to negative anti-Em18 antibody ELISA and PET. It is disputed, whether these patients are truly cured and treatment can be safely discontinued. Our aim was to retrospectively assess long-term outcome of 34 patients with inoperable AE who participated in a previous study to determine feasibility of benzimidazole treatment cessation. Methods: Retrospective analysis of medical charts was undertaken in all 34 AE patients who participated in our previous study. Of particular interest were AE recurrence or other reasons for re-treatment in patients who stopped benzimidazole therapy and whether baseline clinical and laboratory parameters help identify of patients that might qualifiy for treatment cessation. Additionally, volumetric measurement of AE lesions on contrast-enhanced cross-sectional imaging was performed at baseline and last follow-up in order to quantify treatment response. Results: 12 of 34 patients stopped benzimidazole therapy for a median of 131 months. 11 of these patients showed stable or regressive AE lesions as determined by volumetric measurement. One patient developed progressive lesions with persistently negative anti-Em18 antibody ELISA but slight FDG-uptake in repeated PET imaging. At baseline, patients who met criteria for treatment cessation demonstrated higher lymphocyte count and lower total IgE. Conclusion: Treatment cessation is feasible in inoperable AE patients, who demonstrate negative anti-Em18 antibody ELISA and PET on follow-up. Close monitoring including sectional imaging is strongly advised.